NCT07601516CompletedPhase 4
Real World Effectiveness and Safety of Deutetrabenazine in Adult Chinese Participants With Huntington's Disease (HD) Chorea in China
Real-World Effectiveness and Safety of Deutetrabenazine in Chinese Patients With Chorea Associated With Huntington's Disease.
Source: ClinicalTrials.gov · Last updated 27 Aug 2026
Brief summary (registry, in English)
The Primary Objective: To evaluate the real-world effectiveness of deutetrabenazine in adult participants with chorea associated with Huntington's disease in China. The Secondary Objectives: To evaluate the real-world safety of deutetrabenazine in adult participants with chorea associated with Huntington's disease in China.
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 50 (actual)
- First submitted
- 15 May 2026
- Start date
- 2 Feb 2024
- Primary completion date
- 24 Oct 2025
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D LLC
- Diseases
- Huntington's disease
- NCT number
- NCT07601516
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 50
- From 2 Feb 2024 to the primary completion date, 24 Oct 2025
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participants who received reserpine within 20 days of deutetrabenazine treatment initiation
- Participants who received monoamine oxidase inhibitors within 14 days of deutetrabenazine treatment initiation
- Participants who received vesicular monoamine transporter 2 (VMAT2) inhibitors, e.g., tetrabenazine or valbenazine, within 30 days of deutetrabenazine treatment initiation
- Participants who are participating in another study that includes treatment with an investigational drug and/or intervention at the same time as enrolment in the current study
Other illness
- Participants who have an unstable or serious medical or psychiatric illness at baseline
- Participants with any history of suicidality, untreated or inadequately treated depression
Lab values
- Participants with certain comorbidities, including hepatic impairment, congenital long QT syndrome, and clinically significant cardiac arrhythmias.
Other
- Participants unable to provide a written consent for the study.
Who the study is looking for
- Participants with clinically confirmed diagnosis of chorea associated with Huntington's Disease (HD)
- Participants whose baseline total maximal chorea (TMC) score ≥ 8
- Participants who are deutetrabenazine-naïve before study entry or who did not receive deutetrabenazine within 30 days of study entry, and who are about to be treated with deutetrabenazine for chorea associated with HD
- Participants who have provided written consent for the use of personal and medical information for study purposes
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Teva Investigational Site 02 Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
| Teva Investigational Site 03 Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
| Teva Investigational Site 01 Coordinator of this site? Confirm its status | Chengdu | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.